HeartLung.AI

HeartLung.AI is a health-tech company aiming to bring AI-enabled early detection and prevention of cardiovascular disease and lung cancer to mass adoption. Additionally, the AI detects and reports osteoporosis and fatty liver disease. HeartLung.AI received FDA "Breakthrough Designation" for AutoChamber AI that detects enlarged cardiac chambers and left ventricular hypertrophy in non-contrast chest CT scans which are invisible to human eyes. HeartLung cleared FDA 510(k) for AutoBMD which is the only DEXA-equivalent, CT-based opportunistic osteoporosis screening approved by FDA that is applicable to 25+ million CT scans every year and is reimbursed by Medicare. HeartLung is awaiting approval for AI-CVD which includes multiple AI modules including AutoCAC (Automated Coronary Calcium Scoring) focusing on opportunistic screening in chest CT scans. For more information, visit www.heartlung.ai and email contact@heartlung.ai.